Solid Malignancies clinical trials at UCSF
2 research studies open to eligible people
GIM-122 in Subjects With Advanced Solid Malignancies
open to eligible people ages 18 years and up
GIM-122 is a first-in-class, humanized immunoglobulin G1 kappa dual functioning monoclonal antibody (DFA). This phase 1 / 2 study plans to evaluate the safety, tolerability, pharmacokinetics and clinical efficacy of intravenous (IV) administration of GIM-122 in adults with advanced malignancies.
San Francisco, California and other locations
AZD9574 as Monotherapy and in Combination With Anti-cancer Agents in Participants With Advanced Solid Malignancies
open to eligible people ages 18-130
This study will assess the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary efficacy of AZD9574 individually and in combination with anti-cancer agents in 490 participants with advanced cancer that has recurred/progressed.
San Francisco, California and other locations
Our lead scientists for Solid Malignancies research studies include Nicholas Butowski Katy Tsai, MD.
Last updated: